Literature DB >> 16403009

Smad3-null mice lack interstitial cells of Cajal in the colonic wall.

A Vetuschi1, R Sferra, G Latella, A D'Angelo, V Catitti, G Zanninelli, M A Continenza, E Gaudio.   

Abstract

BACKGROUND: Transforming growth factor-beta (TGF-beta)/Smad's signalling pathway plays a pivotal role in organogenesis, oncogenesis, inflammation, repair and fibrosis. The aim of this study was to evaluate the morphology of muscle layers and the density and distribution of interstitial cells of Cajal (ICC) in the colon of Smad3 knockout mice.
MATERIALS AND METHODS: Eighteen Smad3 wild-type mice and 12 null mice were sacrificed at age 4 months and the colons were collected for histology (Haematoxilin-Eosin, Masson thrichrome and Gomori silver staining), morphometry and immunohistochemistry (IHC) analysis. For IHC we used the c-Kit, alpha-smooth muscle actine (alpha-SMA), vimentin, desmin and neuronal cocktail (S-100, NSE, neurofilament 200) antibodies.
RESULTS: When sacrificed, 40% of the null mice showed different degrees of colon dilatation when compared with the wild-type. Histological and morphometric evaluation revealed a significant reduction in muscle layer thickness of the colon in all the null mice when compared with the wild-type. Immunohistochemistry evaluation showed a marked reduction, or even absence, of c-Kit immunoreactivity, which identifies ICC, in the colon of all the null mice, compared with the wild-type.
CONCLUSIONS: Smad3 null mice showed a marked reduction, or even absence, of ICC in the colon together with a concomitant reduction of intestinal smooth muscle layer thickness. This data could account for the colonic dilation observed in approximately 40% of the Smad3 null mice. Alteration of intestinal smooth muscle layers and ICC could also be involved in the resistance of the Smad3 null mice to develop colonic fibrosis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16403009     DOI: 10.1111/j.1365-2362.2006.01593.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  7 in total

1.  Electrical stimulation of gut motility guided by an in silico model.

Authors:  Bradley B Barth; Craig S Henriquez; Warren M Grill; Xiling Shen
Journal:  J Neural Eng       Date:  2017-12       Impact factor: 5.379

2.  Factors associated with successful decrease and discontinuation of antegrade continence enemas (ACE) in children with defecation disorders: a study evaluating the effect of ACE on colon motility.

Authors:  L Rodriguez; S Nurko; A Flores
Journal:  Neurogastroenterol Motil       Date:  2012-10-04       Impact factor: 3.598

3.  IL-9 enhances growth of ICC, maintains network structure and strengthens rhythmicity of contraction in culture.

Authors:  Jing Ye; Yaohui Zhu; Waliul I Khan; Jacques Van Snick; Jan D Huizinga
Journal:  J Cell Mol Med       Date:  2006 Jul-Sep       Impact factor: 5.310

4.  ENDOGLIN/CD105 is expressed in KIT positive cells in the gut and in gastrointestinal stromal tumours.

Authors:  Petra Gromova; Brian P Rubin; An Thys; Pierre Cullus; Christophe Erneux; Jean-Marie Vanderwinden
Journal:  J Cell Mol Med       Date:  2012-02       Impact factor: 5.310

5.  Neurovascular alterations of muscularis propria in the human anterior vaginal wall in pelvic organ prolapse.

Authors:  R Sferra; S Pompili; A D'Alfonso; G Sabetta; E Gaudio; G Carta; C Festuccia; A Colapietro; Antonella Vetuschi
Journal:  J Anat       Date:  2019-05-30       Impact factor: 2.610

Review 6.  The Charming World of the Extracellular Matrix: A Dynamic and Protective Network of the Intestinal Wall.

Authors:  Simona Pompili; Giovanni Latella; Eugenio Gaudio; Roberta Sferra; Antonella Vetuschi
Journal:  Front Med (Lausanne)       Date:  2021-04-16

Review 7.  Cellular and Molecular Mediators of Intestinal Fibrosis.

Authors:  Ian C Lawrance; Gerhard Rogler; Giorgos Bamias; Christine Breynaert; Jon Florholmen; Gianluca Pellino; Shimon Reif; Silvia Speca; Giovanni Latella
Journal:  J Crohns Colitis       Date:  2017-12-04       Impact factor: 9.071

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.